Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers

被引:43
|
作者
Appiah-Kubi, Kwaku [1 ,3 ]
Wang, Ying [1 ]
Qian, Hai [1 ]
Wu, Min [1 ]
Yao, Xiaoyuan [2 ]
Wu, Yan [1 ]
Chen, Yongchang [1 ]
机构
[1] Jiangsu Univ, Sch Med, Dept Physiol, Zhenjiang 212013, Jiangsu, Peoples R China
[2] Changchun Med Coll, Basic Med Dept, Changchun 130013, Jilin, Peoples R China
[3] Univ Dev Studies, Dept Appl Biol, Navrongo, Ghana
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
PDGFR/PDGF system; Therapeutic targets; Prognostic marker; Treatment response biomarker; Small molecules; Immunotherapy; Gene therapy; RENAL-CELL CARCINOMA; RECEPTOR-ALPHA EXPRESSION; COPY NUMBER GAIN; PHASE-II TRIAL; IMATINIB MESYLATE; FACTOR PDGF; MONOCLONAL-ANTIBODY; RNA INTERFERENCE; POTENT INHIBITOR; PROSTATE-CANCER;
D O I
10.1007/s13277-016-5069-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Progress in cancer biology has led to an increasing discovery of oncogenic alterations of the platelet-derived growth factor receptors (PDGFRs) in cancers. In addition, their overexpression in numerous cancers invariably makes PDGFRs and platelet-derived growth factors (PDGFs) prognostic and treatment markers in some cancers. The oncologic alterations of the PDGFR/PDGF system affect the extracellular, transmembrane and tyrosine kinase domains as well as the juxtamembrane segment of the receptor. The receptor is also involved in fusions with intracellular proteins and receptor tyrosine kinase. These discoveries undoubtedly make the system an attractive oncologic therapeutic target. This review covers elementary biology of PDGFR/PDGF system and its role as a prognostic and treatment marker in cancers. In addition, the multifarious therapeutic targets of PDGFR/PDGF system are discussed. Great potential exists in the role of PDGFR/PDGF system as a prognostic and treatment marker and for further exploration of its multifarious therapeutic targets in safe and efficacious management of cancer treatments.
引用
收藏
页码:10053 / 10066
页数:14
相关论文
共 50 条
  • [31] PLATELET-DERIVED GROWTH-FACTOR
    HELDIN, CH
    WASTESON, A
    WESTERMARK, B
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1985, 39 (03) : 169 - 187
  • [32] PLATELET-DERIVED GROWTH-FACTOR
    ROSS, R
    ANNUAL REVIEW OF MEDICINE, 1987, 38 : 71 - 79
  • [33] PLATELET-DERIVED GROWTH-FACTOR
    ROSS, R
    LANCET, 1989, 1 (8648): : 1179 - 1182
  • [34] PLATELET-DERIVED GROWTH-FACTOR
    ROSS, R
    RAINES, E
    KARIYA, B
    VOGEL, A
    JOURNAL OF SUPRAMOLECULAR STRUCTURE, 1979, : 175 - 175
  • [35] PLATELET-DERIVED GROWTH-FACTOR .3. IDENTIFICATION OF A PLATELET-DERIVED GROWTH-FACTOR RECEPTOR BY AFFINITY LABELING
    GLENN, K
    BOWENPOPE, DF
    ROSS, R
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1982, 257 (09) : 5172 - 5176
  • [36] THE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR IS PHYSICALLY ASSOCIATED WITH A PLATELET-DERIVED GROWTH FACTOR-SENSITIVE PHOSPHATIDYLINOSITOL KINASE
    COUGHLIN, SR
    ESCOBEDO, JA
    WILLIAMS, LT
    CLINICAL RESEARCH, 1988, 36 (03): : A270 - A270
  • [37] PLATELET-DERIVED GROWTH-FACTOR
    BOWENPOPE, DF
    ROSS, R
    CLINICS IN ENDOCRINOLOGY AND METABOLISM, 1984, 13 (01): : 191 - 205
  • [38] PLATELET-DERIVED GROWTH-FACTOR RECEPTOR SIGNALS
    CLAESSONWELSH, L
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (51) : 32023 - 32026
  • [39] Platelet-derived growth factor and arterial response to injury
    Hart, CE
    Clowes, AW
    CIRCULATION, 1997, 95 (03) : 555 - 556
  • [40] Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma
    Katano, M
    Nakamura, M
    Fujimoto, K
    Miyazaki, K
    Morisaki, T
    ANNALS OF SURGERY, 1998, 227 (03) : 365 - 371